A detailed history of Janus Henderson Group PLC transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 5,216,342 shares of CMPX stock, worth $9.91 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,216,342
Previous 6,492,900 19.66%
Holding current value
$9.91 Million
Previous $12.9 Million 59.42%
% of portfolio
0.0%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.0 - $1.85 $1.28 Million - $2.36 Million
-1,276,558 Reduced 19.66%
5,216,342 $5.22 Million
Q1 2024

May 15, 2024

SELL
$1.2 - $2.29 $65,197 - $124,417
-54,331 Reduced 0.83%
6,492,900 $12.9 Million
Q4 2023

Feb 14, 2024

SELL
$1.4 - $1.98 $158,769 - $224,545
-113,407 Reduced 1.7%
6,547,231 $10.2 Million
Q3 2023

Nov 14, 2023

BUY
$1.87 - $3.25 $826,347 - $1.44 Million
441,897 Added 7.11%
6,660,638 $13.1 Million
Q2 2023

Aug 14, 2023

BUY
$2.64 - $3.48 $565,667 - $745,652
214,268 Added 3.57%
6,218,741 $19.8 Million
Q1 2023

May 15, 2023

BUY
$3.14 - $5.48 $204,674 - $357,202
65,183 Added 1.1%
6,004,473 $19.6 Million
Q4 2022

Feb 14, 2023

BUY
$2.55 - $5.41 $6.16 Million - $13.1 Million
2,416,310 Added 68.59%
5,939,290 $29.9 Million
Q3 2022

Nov 14, 2022

BUY
$1.9 - $3.37 $334,037 - $592,476
175,809 Added 5.25%
3,522,980 $8.07 Million
Q2 2022

Aug 15, 2022

BUY
$1.43 - $3.1 $220,044 - $477,018
153,877 Added 4.82%
3,347,171 $8.8 Million
Q1 2022

May 16, 2022

BUY
$1.25 - $3.5 $2.15 Million - $6.02 Million
1,720,683 Added 116.85%
3,193,294 $4.33 Million
Q4 2021

Feb 14, 2022

BUY
$2.88 - $3.98 $4.24 Million - $5.86 Million
1,472,611 New
1,472,611 $4.7 Million

Others Institutions Holding CMPX

About Compass Therapeutics, Inc.


  • Ticker CMPX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 101,285,000
  • Market Cap $192M
  • Description
  • Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...
More about CMPX
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.